Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Bevacizumab · Alymsys, Mvasi

Monoclonal antibody · Inhibitor of Vascular endothelial growth factor A (VEGFA) · developed by Genentech

Approved FDA, Feb 2004
2 Registered trials

What is Bevacizumab?

Bevacizumab is an approved antibody studied in Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration.

At a glance

Also known as
Alymsys, Mvasi, Vegzelma, Zirabev, ONS-5010, HD204
Drug type
Monoclonal antibody
Targets
Vascular endothelial growth factor A (VEGFA)
Mechanism
Inhibitor of Vascular endothelial growth factor A (VEGFA)
Pathways
angiogenesis, endothelial cell proliferation
Therapy area
Ophthalmology
Developer
Genentech
In trials of
EDSA, OTLK
FDA status
Approved as Alymsys, Mvasi, Vegzelma (February 26, 2004), BLA125085 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 21, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05112861 Phase 3 Age-Related Macular Degeneration Active not recruiting OTLK
NCT06701656 Phase 2 Acute Respiratory Distress Syndrome (ARDS) Recruiting EDSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)Age-Related Macular DegenerationARDSARDS (Acute Respiratory Distress Syndrome)BRVO - Branch Retinal Vein OcclusionDiabetic Macular EdemaNeovascular Age-related Macular DegenerationWet Macular Degeneration

Other drugs acting on VEGFA

ABP 938 FDA approved Aflibercept FDA approved Ivonescimab Phase 3 Pumitamig Phase 2/3 Tovecimig Phase 2/3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.